Author

M. Atsukawa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. S. Perelson· 1 shared C. Kawamoto· 1 shared C. Kondo· 1 shared D. Miura· 1 shared E. Kawakami· 1 shared H. Harimoto· 1 shared H. Takahashi· 1 shared K. Aihara· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. S. Perelson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Prediction of elimination of intrahepatic cccDNA in hepatitis B virus-infected patients by a combination of noninvasive viral markers

S. Iwami, M. Iwamoto, T. Wakita, K. Watashi, A. S. Perelson, Y. Tanaka, M. Dandri, K. Aihara, M. Muramatsu, S. Iwami, E. Kawakami, L. Allweiss, P. Tangkijvanich, N. Chuaypen, M. Atsukawa, , Y. Fujita

This study develops a noninvasive method using viral markers to predict cccDNA levels in HBV patients, validated against liver biopsy data.

bioRxiv · Nov 4, 2022 · PreprintMicrobiology

Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression

T. Masu, M. Atsukawa, K. Nakatsuka, M. Shimizu, D. Miura, T. Arai, H. Harimoto, C. Kondo, K. Kaneko, S. Futagami, C. Kawamoto, H. Takahashi, K. Iwakiri

This study shows that combining anti-CD137 mAb with trastuzumab enhances NK cell-mediated ADCC against HER2-low pancreatic cancer cells, particularly in individuals with FcγRIIIA-VV/VF genotype.

bioRxiv · Jul 3, 2018Immunology